NCT06137573View on ClinicalTrials.gov

Human Mass Balance and Biotransformation Study of [14C]TNP-2198

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

September 1, 2022

Study Completion Date

September 1, 2022

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

[14C]TNP-2198

600mg suspension containing 150μCi of \[14C\] TNP-2198

Trial Locations (1)

Unknown

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

TenNor Therapeutics (Suzhou) Limited

INDUSTRY